De Novo Development of Distal Jejunal and Duodenal Adenomas after 41 Months of Teduglutide Treatment in a Short Bowel Patient: A Case Report.

The GLP-2 analogue teduglutide is a medical treatment option for short bowel syndrome associated chronic intestinal failure patients. Since studies in mice have shown that GLP-2 analogues may promote the growth of colonic neoplasms, surveillance colonoscopies before and during teduglutide therapy were recommended. The occurrence of small intestinal neoplasms has not been reported so far, except for a recent report about de novo development of hamartomatous duodenal polyps. We report a case of de novo development of small intestinal pre-malignant adenomatous polyps in both bulbar duodenum and distal jejunum in a patient treated with teduglutide for 41 months. Therefore, additional endoscopic surveillance of the upper gastrointestinal tract may be advised during teduglutide therapy for early detection and removal of potential small bowel adenomas. This article is protected by copyright. All rights reserved.